Gujarat Themis Biosyn Stock Price - ₹425.10 | Healthcare

‌
‌
‌

The Quarter story

The two most recent quarterly results, compared side-by-side.

Gujarat Themis Biosyn sustains strong revenue growth and healthy margins, though rising costs and working capital pressures require attention.

Revenue expands from ₹35.9 Cr to ₹43.8 Cr from Q1 FY26 to Q1 FY27 as core sales remain robust.

Interest costs surge from ₹0.04 Cr to ₹1.79 Cr from Q1 FY26 to Q1 FY27 as debt servicing increases.

EBITDA margin expands from 38.8% to 47.5% from Q1 FY26 to Q1 FY27 as pricing power endures.

Trade receivables jump from ₹35.14 Cr to ₹60.92 Cr from Q2 FY26 to Q4 FY26 as collection cycles lengthen.

Profit after tax rises from ₹9.1 Cr to ₹11.1 Cr from Q1 FY26 to Q1 FY27 as net profitability stabilizes.

Material costs rise from ₹6.83 Cr to ₹7.73 Cr from Q1 FY26 to Q1 FY27 as input pricing normalizes.

Borrowings increase from ₹68.70 Cr to ₹128.06 Cr from Q2 FY26 to Q4 FY26 as funding needs scale.

‌
‌
‌

In the news

Gujarat Themis Biosyn Stock Surges 40% in 6 Months After QIP

Gujarat Themis Biosyn surges 6% on QIP approval, Q1 profit up 22%

Gujarat Themis Biosyn Q1 profit jumps 22.19% to ₹11.07 cr

Gujarat Themis Biosyn shares jump 5% on ₹1,300 cr Japan acquisition

Gujarat Themis Biosyn acquires Japanese firm for ₹1,300 crore

Gujarat Themis Biosyn acquires Japan's MicroBiopharm for ₹1,300 cr

Gujarat Themis Biosyn surges 15% on €158M Sanofi acquisition